GC Biopharma receives a organization license for the design of a plasma fractionation plant and technological innovation transfer in Indonesia

YONGIN, South Korea, June 1, 2023 /PRNewswire/ — GC Biopharma, a South Korean biopharmaceutical business, declared on Jun. 1st that it has successfully attained last acceptance from the Indonesian Ministry of Wellbeing for the development of a plasma fractionation plant and technological know-how transfer.

(PRNewsfoto/GC Biopharma)

Before in Jan., the company was effectively selected by the Indonesian govt as the most well-liked bidder for the license of plasma fractionation plant construction and technological innovation transfer business. Right after some detailed session and good-tuning discussions, the corporation has gained an formal acceptance recognize for the organization.

GC Biopharma is the only corporation worldwide that has efficiently done the turnkey task of a plasma fractionation plant in an abroad industry. Given that its initially export of a plasma fractionation plant to Thailand, GC Biopharma has been accumulating abilities and know-how in abroad plant design via profitable assignments in various nations such as China and Canada.

The plant project is the Indonesian government’s roadmap to acknowledging a stable and self-enough supply of plasma derivatives derived from the plasma of Indonesian individuals. At this time, the county relies 100 p.c on imported plasma derivatives.

“The undertaking will be yet another chance for us to be internationally recognized for our remarkable plasma fractionation technology and the company’s 50 percent-century legacy”, spelled out GC Biopharma and additional that the certain deal dimensions and other information will be announced after the formal deal is signed. This challenge retains significance in that it is a outcome of steady endeavours and collaboration among the Korean federal government and the private sector in the area of biopharmaceuticals, foremost to successful bidding from a international federal government.

GC Biopharma initially began creating albumin in the 1970s and given that then on, it has been creating numerous plasma derivatives. At the moment, the corporation supplies 12 items to 32 nations globally from its Ochang plant. Proven in 2009, the Ochang plant is Asia’s most significant plasma fractionation plant.

About GC Biopharma

GC Biopharma (formerly recognised as Green Cross Company) is a biopharmaceutical organization that delivers lifestyle-preserving and lifetime-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the foremost plasma protein and vaccine product or service suppliers globally and has been committed to top quality health care answers for extra than 50 percent a century.

This press release might consist of biopharmaceuticals in ahead-looking statements, which express the current beliefs and anticipations of GC Biopharma’s management. These statements do not depict any assurance by GC Biopharma or its administration of long run effectiveness and contain acknowledged and unknown risks, uncertainties and other factors. GC Biopharma undertakes no obligation to update or revise any forward-hunting assertion contained in this press release or any other forward-on the lookout statements it may perhaps make, except as needed by regulation or inventory exchange rule.

GC Biopharma Contacts (Media)

Seunghyun Baek
seunghyun.baek@gccorp.com

Sohee Kim
shkim20@gccorp.com

Yelin Jun
yelin@gccorp.com

 

 

Cision

Cision

View first content to down load multimedia:https://www.prnewswire.com/information-releases/gc-biopharma-gets-a-company-license-for-the-design-of-a-plasma-fractionation-plant-and-technological know-how-transfer-in-indonesia-301840768.html

Source GC Biopharma